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Abstract
Ferroptosis is a cell death process driven by damage to cell membranes and linked to
numerous human diseases. Ferroptosis is caused by loss of activity of the key enzyme that
is tasked with repairing oxidative damage to cell membranes—glutathione peroxidase 4
(GPX4). GPX4 normally removes the dangerous products of iron-dependent lipid peroxida-
tion, protecting cell membranes from this type of damage; when GPX4 fails, ferroptosis
ensues. Ferroptosis is distinct from apoptosis, necroptosis, necrosis, and other modes of
cell death. Several key mysteries regarding how cells die during ferroptosis remain
unsolved. First, the drivers of lipid peroxidation are not yet clear. Second, the subcellular
location of lethal lipid peroxides remains an outstanding question. Finally, how exactly lipid
peroxidation leads to cell death is an unsolved mystery. Answers to these questions will pro-
vide insights into the mechanisms of ferroptotic cell death and associated human diseases,
as well as new therapeutic strategies for such diseases.
Introduction
The fundamental building block of life is the cell, the smallest living unit within multicellular
organisms. Cells, like the organisms they constitute, live and die. According to the recommen-
dations of the Nomenclature Committee on Cell Death (NCCD), cell death can be accidental or
regulated [1]. Accidental cell death occurs when cells experience overwhelming physical, chemi-
cal, or mechanical insults; such accidental cell death cannot be modulated by molecularly tar-
geted interventions. In contrast, regulated cell death can be modulated pharmacologically and
genetically, as it is controlled by molecular mechanisms. The NCCD defines programmed cell
death to be a subset of regulated cell death that occurs in normal physiological contexts [1]. Cas-
pase-dependent apoptosis is a well-known form of regulated, programmed cell death. Ferropto-
sis is a recently described form of cell death that is regulated [2], in the sense of the NCCD
definition, as it can be enhanced and suppressed by specific genetic and pharmacological inter-
ventions. Ferroptosis is characterized by loss of activity of glutathione peroxidase 4 (GPX4),
resulting in overwhelming accumulation of lethal lipid peroxides [3] (Fig 1).
Ferroptosis was originally coined as a term for the unique form of cell death initated by the
small molecules erastin and RAS-selective lethal 3 (RSL3) [3] and is now defined as a form of
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cell death that involves accumulation of lipid peroxides and that is suppressed by iron chelators
and lipophilic antioxidants [2]. Other compounds that induce cytosolic or mitochondrial reac-
tive oxygen species (ROS) do not induce ferroptosis [3,4]; thus, general ROS production is not
related to ferroptosis. In contrast, ferroptosis is tightly linked to lipid peroxidation and can be
thought of as death by lipid peroxidation. An open question is whether any type of lethal lipid
peroxidation is classified as ferroptosis or whether only certain types of lethal lipid peroxida-
tion should be termed ferroptosis. Since the current definition of ferroptosis is a cell death pro-
cess involving lipid peroxidation that is suppressed by both iron chelators and lipophilic
antioxidants, any lethal iron-dependent lipid peroxidation would be classified as ferroptosis.
However, just as elucidation of the mechanisms driving apoptosis has revealed different path-
ways leading to a similar endpoint, such as the instrinsic and extrinsic apoptotic pathways, it
may be that ferroptosis can be initiated and executed by distinct pathways involving different
types of lethal iron-dependent lipid peroxidation. More details on the specific mechanisms
involved in lethal lipid peroxidation will be needed to resolve this question.
Ferroptosis has been implicated in numerous human pathologies and therapeutic strategies,
but a normal physiological function for ferroptosis has not been identified, except perhaps as a
tumor suppression mechanism. A recent review summarized the evidence for ferroptosis in
models of a variety of degenerative diseases of the kidney, heart, liver, and brain, including
models of Parkinson, Huntington, and Alzheimer diseases, dementia, and traumatic and hem-
orrhagic injuries [2].
Pathologies involving ferroptosis have also been found in contexts in which iron is abun-
dant, such as in red blood cells. Indeed, ferroptosis has been implicated in the complications of
blood transfusions. A recent study found that transfusion of storage-damaged red blood cells
induces a macrophage-dependent inflammatory response by Ly6Chi monocytes [5]. Moreover,
macrophages underwent ferroptosis following phagocytosis of storage-damaged red blood
cells. This suggests that inhibitors of ferroptosis might improve outcomes of blood transfusion.
Ferroptosis has also been linked to the iron-overload disease liver hemochromatosis [2].
As noted above, there are few reports of natural functions of ferroptosis. However, the p53
tumor suppressor has been suggested to use ferroptosis as a tumor suppression mechanism
[6,7], suggesting that ferroptosis may have a natural function in suppressing the developing of
some tumors in mammals.
Ferroptosis also may be useful for eliminating cancer cells that have become dependent on
suppression of ferroptosis for their surivival. Two recent studies found that some of the most
drug-resistant and hard-to-kill cancer cells—namely, those that have undergone epithelial-to-
mesenchymal transition [8] and those that persist after conventional chemotherapy or targeted
therapy [9]—are highly sensitive to GPX4 inhibitors and ferroptosis in general. This suggests
that ferroptosis-inducing agents might be developed as a new class of cancer therapies.
Finally, ferroptosis may be involved in the toxic effects of environmental contaminants. A
recent report found that mice fed arsenite in their drinking water exhibited increased neuronal
ferroptosis [10]. Thus, ferroptosis markers may aid in detecting individuals exposed to arsenite
in their drinking water, and ferroptosis inhibitors might be useful for such communities.
Four ways of initiating ferroptosis have been discovered (Table 1) [3]. Class 1 ferroptosis
inducers act by starving cells of the amino acid cysteine. Such compounds act by inhibiting
system xc
−, a transmembrane cystine-glutamate antiporter, which imports cystine (the oxi-
dized, disulfide form of cysteine) into cells. When this process is blocked, cysteine is depleted
from these cells.
Cysteine has a number of functions in cells—most importantly, in the context of ferropto-
sis, as a building block for the biosynthesis of glutathione (GSH). GSH is a cofactor and sub-
strate for GPX4 and is required for the lipid repair function of this enzyme. Depletion of GSH
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through cysteine starvation leads to loss of GPX4 activity, resulting in accumulation of unre-
paired lipid peroxides and death by ferroptosis.
Erastin and its more potent analogs imidazole ketone erastin (IKE) and piperazine erastin
(PE), as well as the FDA-approved drugs sulfasalazine and sorafenib, are small molecule class 1
ferroptosis inducers. In addition, high extracellular concentrations of the amino acid neuro-
transmitter glutamate can act as a class 1 ferroptosis inducer. All of these are suitable for use in
vitro, although, as sorafenib and glutamate also activate other nonferroptotic mechanisms,
they must be used with care as chemical probes of ferroptosis. Erastin has low solubiity and
poor metabolic stability and pharmacokinetics, preventing its use in vivo. Likewise, sulfasala-
zine has low metabolic stability and low potency, preventing its reliable use in vivo. However,
Fig 1. Pathways regulating ferroptosis. Summary of ferroptosis mechanisms and signaling pathway. Ferroptosis inducers/sensitizers are colored red. Ferroptosis
inhibitors are colored green. 2,2-BP, 2,2-bipyridyl; ACSL4, acyl-CoA synthetase long chain family member 4; ALOX, arachidonate lipoxygenase; BHT, butylated
hydroxytoluene; CoQ10, coenzyme Q10; CPX, ciclopirox olamine; DFO, deferoxamine; D-PUFA, deuterated polyunsaturated fatty acids; Fer-1, ferrostatin-1; FIN56,
ferroptosis inducer 56; FINO2, ferroptosis inducer endoperoxide; GPX4, glutathione peroxidase 4; GSSG, glutathione disulfide; HMG-CoA, β-hydroxy β-
methylglutaryl-CoA; IKE, imidazole ketone erastin; LPCAT3, lysophosphatidylcholine acyltransferase 3; PL-PUFA (PE), polyunsaturated-fatty-acid-containing
phospholipids; PL-PUFA(PE)-OOH, polyunsaturated-fatty-acid-containing-phospholipid hydroperoxides; PUFA, polyunsaturated fatty acid; ROS, reactive oxygen
species; RSL3, RAS-selective lethal 3
https://doi.org/10.1371/journal.pbio.2006203.g001
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sorafenib, IKE, and PE are suitable for in vivo use, as they have high potency, sufficient meta-
bolic stability, and acceptable pharmacokinetic profiles.
Class 2 ferroptosis inducers act through direct inhibition of GPX4. RSL3 (also known as
[1S,3R]-RSL3 to indicate the stereochemical configuration) and a number of other reported
compounds [11] covalently interact with the nucleophilic active-site selenocyteine of GPX4
and inhibit its enzymatic activity, resulting in loss of its lipid repair function, accumulation of
lethal lipid peroxides, and consequent cell death [12]. RSL3 is primarily suitable for in vitro
use as a potent and selective inhibitor of GPX4; its inactive stereoisomer (1R, 3R)-RSL3 is a
useful inactive negative control compound. Unfortunately, none of the class 2 ferroptosis
inducers are suitable for in vivo use, due to low solubility and difficulty characterizing their
pharmacokinetics. However, numerous genetic studies in vivo have examined the effects of
loss of the gpx4 gene.
Class 3 ferroptosis inducers, which include the compounds ferroptosis inducer 56 (FIN56)
and caspase-independent lethal 56 (CIL56), act by depleting GPX4 protein from cells and
simultaneously causing depletion of mevalonate-derived coenzyme Q10 (CoQ10), which func-
tions as an endogenous lipophilic antioxidant in addition to its well-known function in the
mitochondrial electron transport chain [13]. CIL56 also activates a distinct necrotic cell death
mechanism, whereas FIN56 is a specific inducer of ferroptosis; thus, FIN56 is the more specific
chemical probe for in vitro use. Neither compound has been used in vivo.
Table 1. Ferroptosis inducers.




Inhibition of system xc
− Prevents cystine import, causes GSH depletion and loss of
GPX4 activity






Direct inhibition of GPX4 Covalently interacts with GPX4 and inhibits its enzymatic
activity





Depletion of GPX4 protein
and CoQ10
Depletes GPX4 protein and simultaneously causes
depletion of CoQ10 via SQS-mevalonate pathway





Oxidizes iron, drives lipid peroxidation and indirect
inactivation of GPX4
FINO2 Unknown
Others: BSO, DPI2, cisplatin, cysteinase, statins, ferric ammonium citrate, trigonelline, CCI4, silica-based nanoparticles, nonthermal plasma
Abbreviations: BSO, buthionine sulfoximine; CCI4, carbon tetrachloride; CIL56, caspase-independent lethal 56; CoQ10, coenzyme Q10; DPI, diverse pharmacological
inhibitor; FIN56, ferroptosis inducer 56; FINO2, ferroptosis inducer endoperoxide; GPX4, glutathione peroxidase 4; GSH, glutathione; IKE, imidazole ketone erastin;
ML162, Molecular Libraries 162; PE, piperazine erastin; RSL3, RAS-selective lethal 3; SQS, squalene synthase
https://doi.org/10.1371/journal.pbio.2006203.t001
Table 2. Ferroptosis inhibitors.
Class Class Characteristics Impact on Ferroptosis Compound Examples Suitable for In Vivo Use
Class
1
Iron chelators Deplete iron and prevent iron-dependent lipid
peroxidation










D-PUFAs Prevents initiation and propagation of lipid
peroxidation
D4-arachidonic acid, D10-docosahexaenoic acid Yes
Class
4
LOX inhibitors Inactivate LOX and block LOX-induced lipid
peroxidation
CDC, baicalein, PD-146176, AA-861, zileuton Not sufficiently selective in
most cases
Others: glutaminolysis inhibitors, cycloheximide, beta-mercaptoethanol, dopamine, selenium, vildagliptin.
Abbreviations: AA, arachidonic acid; BHT, butylated hydroxytoluene; CoQ10, coenzyme Q10; D-PUFA, deuterated polyunsaturated fatty acid; Fer-1, ferrostatin-1; LOX,
lipoxygenase
https://doi.org/10.1371/journal.pbio.2006203.t002
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The only class 4 ferroptosis inducer currently known is ferroptosis inducer endoperoxide
(FINO2), which acts by oxidizing iron, indirectly inactivating GPX4, and further driving lipid
peroxidation [14,15]. This compound is suitable for use in vitro and has not been evaluated in
vivo, although its moderate potency suggests it might not be effective in vivo. A recent report
suggested that nonthermal plasma may be able to similarly redox cycle iron and perhaps
induce ferroptosis through this class 4 mechanism [16].
Blocking ferroptosis may be useful in treating some degenerative diseases. A number of fer-
roptosis inhibitors that could be used for such purposes have been reported (Table 2). The first
two types of ferroptosis inhibitors identified, as noted above, were iron chelators—such as
deferoxamine and ciclopirox—and lipophilic antioxidants—such as α-tocopherol (a compo-
nent of vitamin E), butylated hydroxytoluene (BHT), ferrostatin-1 (Fer-1), and liproxstatin-1.
Iron chelators prevent the initiation of lipid peroxidation by inhibiting lipoxygenases (LOXs)
and the propagation of lipid peroxidation by suppressing Fenton chemistry. Deferoxamine
and ciclopirox are suitable for in vivo use; both are drugs approved for human use. Lipophilic
antioxidants likely exert their effects through a radical trapping mechanism to suppress lipid
peroxidation [17] [18]. In addition, other ferroptosis inhibitors have been identified, including
deuterated polyunsaturated fatty acids (D-PUFAs), inhibitors of acyl-CoA synthetase long
chain family member 4 (ACSL4), glutaminolysis inhibitors, LOX inhibitors, cycloheximide,
beta-mercaptoethanol, dopamine, selenium, and vildagliptin [2]. Table 2 summarizes the util-
ity of these compounds in vitro and in vivo.
Several studies have examined which lipids undergo peroxidation during ferroptosis. Lipi-
domic studies revealed that polyunsaturated-fatty-acid-containing phospholipids (PUFA-PLs)
are the lipids most susceptible to peroxidation and drive the subsequent cell death (Fig 1). Bis-
allylic carbons (carbon atoms that are adjacent to two neighboring carbon–carbon double
bonds) in such PUFA-PLs are chemically susceptible to attack by radicals, LOXs, and oxygen,
making these the key positions within lipids that drive ferroptosis [19]. PUFA-PLs are the
most vulnerable lipid species, due to the presence of these bis-allylic sites in the membrane
environment. It is worth noting that for death to proceed, free PUFAs must be incorporated
into phospholipids by ACSL4 and lysophosphatidylcholine acyltransferase 3 (LPCAT3)
[20,21] (Table 3).
There are several key outstanding questions in the lipid peroxidation process that drives fer-
roptosis. First, what causes lipid peroxidation—nonenzymatic pathways, i.e., Fenton chemis-
try, or enzymatic processes, such as LOXs? Second, what is the location in which lipid
peroxidation takes place during ferroptosis? Does this event occur in the plasma membrane,
mitochondria, endoplasmic reticulum (ER), lysosomes, and/or other subcellular locations?
Third, how does lipid peroxidation lead to ferroptotic cell death? Does this stem from damage
to specific membranes or through downstream generation of reactive products of lipid
Table 3. Key ferroptosis-related genes.
Gene Name Function
ACSL4 Acyl-CoA synthetase long chain family member 4 Converts free fatty acids into fatty CoA ester, required for ferroptosis
ALOXs Arachidonate lipoxygenases Catalyze peroxidation of AAs (PUFAs)
GPX4 Glutathione peroxidase 4 Reduces LOOHs in membrane phospholipids to suppress ferroptosis
LPCAT3 Lysophosphatidylcholine acyltransferase 3 Involved in biosynthesis of phospholipids, required for ferroptosis
Abbreviations: AA, arachidonic acid; LOOH, lipid hydroperoxide; PUFA, polyunsaturated fatty acid
https://doi.org/10.1371/journal.pbio.2006203.t003
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peroxidation? Here, we discuss each of these three unsolved mysteries and provide insight on
how these mysteries might be solved.
What causes lipid peroxidation: Fenton chemistry or LOXs?
Oxidative damage to PUFA-PLs can take place via two mechanisms: the nonenzymatic free-
radical chain reaction involving Fenton chemistry and enzymatic processes, most notably
LOXs. Fenton chemistry refers to a series of reactions between peroxides and divalent ferrous
salts to produce oxygen-centered radicals [22]. Under normal conditions, cellular iron is
under precise regulation. However, there is a pool of loosely chelated iron in cells: while most
cellular iron is bound to heme, there is soluble and chelatable ferrous iron in the cytoplasm
which forms the labile iron pool [23]. This labile iron pool is the likely source of Fenton chem-
istry that generates hydroxyl and peroxyl radicals that are able to abstract hydrogen atoms
from bis-allylic carbons of PUFAs and then cause peroxidation of PUFA-PLs (Fig 2). These
reactions can be terminated by antioxidants and radicals [24]. Recent studies found that
numerous inhibitors of ferroptosis—including Fer-1, liproxstatin-1, and numerous LOX
inhibitors—act as radical trapping antioxidants to prevent the autooxidation and nonenzy-
matic destruction of membrane PUFA-PLs likely driven by Fenton chemistry during ferropto-
sis [25,26]. Moreover, addition of excess iron to cells sensitizes them to ferroptosis [3].
There are three well-defined classes of lipid oxidation enzymes: cyclooxygenases (COXs),
cytochrome p450 (CYPs), and LOXs, among which LOX enzymes have been found to be the
most important for ferroptosis. LOXs are a family of nonheme, iron-containing enzymes that
Fig 2. Fenton chemistry and lipid peroxidation in ferroptosis. There are three steps involved in nonenzymatic lipid peroxidation. The first step is the generation of
lipid radicals (initiation). The second step is the creation of new lipid radicals (propagation). The final step is termination, either by antioxidants or another radical.
PUFA, polyunsaturated fatty acid.
https://doi.org/10.1371/journal.pbio.2006203.g002
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catalyze dioxygenation of PUFAs [27]. In the case of arachidonic acid (AA), there are 6 arachi-
donate lipoxygenase (ALOX) genes in humans: ALOX5, ALOX12, ALOX12B, ALOX15,
ALOX15B, and ALOXE3 [12]. The 5-lipoxygenase enzyme, encoded by the ALOX5 gene, oxi-
dizes AA at carbon 5 and then forms 5-hydroperoxyeicosatetraenoic acid (5-HPETE). The 12-
and 15- lipoxygenases are encoded by ALOX12/ALOX12B and ALOX15/ALOX15B, respec-
tively, and are able to convert AA to 12-HPETE and 15-HPETE [28].
The mechanisms by which LOXs drive ferroptotic cell death, and the isoforms that drive
this process, remain elusive. Several hypotheses have been proposed. One research group
found that in mouse embryonic fibroblasts (MEF), 12/15-lipoxygenase-deficient cells were
resistant to the lethality normally caused by GSH depletion using the GSH biosynthesis inhibi-
tor buthionine sulfoximine (BSO) [29]. Another group found that silencing either ALOX15B
or ALOXE3 prevented erastin-induced cell death, which supported the hypothesis that LOXs
are required for ferroptosis initiated by class 1 inducers [12]. In addition, several LOX inhibi-
tors were found to prevent erastin-induced ferroptosis in MEFs and pancreatic cancer cells
[30,31]; however, as noted above, many LOX inhibitors also act as radical trapping antioxi-
dants that suppress nonenzymatic propagation of lipid peroxidation. It has, however, been
found that tumor cell ferroptosis is promoted by 15-lipoxygenase-catalyzed lipid peroxidation
in cellular membranes [32].
The hypothesis that ALOX5 is involved in initiating ferroptosis was supported by the obser-
vation that deuteration at the 7 position of AA was protective against ferroptosis initiated by
RSL3 [15]. Deuterium is heavier than hydrogen, and because of the primary deuterium isotope
effect, removing a deuterium atom is significantly slower than removing a hydrogen atom to
initiate peroxidation. As a consequence, PUFAs with deuterium at the bis-allylic carbons are
unable to undergo peroxidation. Since the 7 position is the site of ALOX5 peroxidation, this
result is consistent with a role for ALOX5. On the other hand, it is possible that the location of
the 7 postion in the phospholipid membrane renders it more reactive to peroxidation overall
so that substitutions at that position would have a larger effect on the rate of peroxidation. In
summary, current data support a model in which both LOXs and nonenzymatic Fenton chem-
istry contribute to lipid peroxidation during ferroptosis.
Where does lipid peroxidation take place?
Another important question is the location of lipid peroxidation during ferroptosis (Fig 3). A
default assumption has been that lipid peroxidation occurs in the plasma membrane during
ferroptosis because peroxidation of PUFA-PLs in the plasma membrane could compromise
the integrity of cells. However, in addition to the plasma membrane, lipid peroxidation can
also occur in other subcellular locations. Among these, mitochondria, ER, and lysosomes are
three plausible candidates for the sites of lethal lipid peroxidation during ferroptosis.
Unlike apoptosis, ferroptosis in cancer cells doesn’t involve mitochondrial damage but is
accompanied by alterations in mitochondrial morphology and intergrity [3]. Moreover, GPX4
has three isoforms located in the cytosol, nucleus, and mitochondria, and the nitroxide antiox-
idant XJB-5-131 targeted to mitochondria was discovered to be a more potent ferroptosis
inhibitor than nontargeted nitroxides [33]. Thus, the hypothesis emerged that lipid peroxida-
tion occurs in mitochondria during ferroptosis. However, direct evidence linking mitochon-
drial lipid peroxidation to ferroptotic cell death is still lacking. Recently, we generated
mitochondria-deficient cells by introducing the E3 ligase Parkin and inducing mitochondria
uncoupling with carbonyl cyanide m-chlorophenyl hydrazone (CCCP); this results in elimina-
tion of mitochondria through mitophagy [34]. We then treated the mitochondria-deficient
cells with different ferroptosis inducers. The cells lacking mitochondria still underwent
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ferroptosis, indicating that the presence of mitochondria is not necessary for ferroptosis [35].
We also measured total ROS levels in mitochondria-deficient cells and in normal cells. As
expected, we detected increased ROS in the presence of IKE, even in cells lacking mitochon-
dria, albeit to a lesser extent compared to mitochondria-replete cells. These data suggest that
lipid peroxidation does occur in mitochondria but is not required for ferroptosis.
The ER contains the largest pool of lipids in cells. Lipid peroxidation is thus likely to occur
in the ER [36]. However, the relationship between ER lipid peroxidation and ferroptosis is still
mysterious. ER stress and the unfolded protein response (UPR) might be related to ferroptosis.
ER stress is caused by the accumulation of unfolded/misfolded proteins, which can be caused
by a number a pathophysiological disturbances, including glucose deprivation, hypoxia, aber-
rant Ca2+ regulation, and viral infection. [37,38]. ER stress activates a complex signaling net-
work—termed the UPR—to reduce ER stress and restore homeostasis [39].
Inhibition of system xc
− by erastin and the clinically approved anticancer drug sorafenib
triggers some aspects of ER stress as well as ferroptosis, indicating a possible link between ER
stress and ferroptosis [40]. One research group proposed that ROS are a signal generated by
ER stress and UPR activation, consistent with their observation that antioxidant treatment
reduces oxidative stress and UPR activation [41]. Another study showed that ER oxidoreduc-
tion-1 (ERO1) can trigger ROS generation in the ER by oxidizing protein disulfide isomerase
Fig 3. Subcellular model of the location of lipid peroxidation in ferroptosis. The red question marks represent the unsolved mysteries discussed in the
article. 4-HNE, 4-hydroxynonenal; MDA, malondialdehyde; PL-PUFA(PE)-OOH, polyunsaturated-fatty-acid-containing-phospholipid hydroperoxides;
ROS, reactive oxygen species.
https://doi.org/10.1371/journal.pbio.2006203.g003
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(PDI) using a flavin adenine dinucleotide (FAD)-dependent reaction [42]. ER stress, ROS gen-
eration, and ferroptosis are possibly related, but the mechanisms driving lipid peroxidation in
the ER and its relationship to ferroptosis are still unclear.
Lysosomes are another subcellular compartment hypothesized to be involved in lipid per-
oxidation during the course of ferroptosis, supported by the fact that ferrostatins accumulate
in lysosomes using stimulated Raman scattering (SRS) microscopy [35]. It has been found that
ROS are constitutively generated in lysosomes, using fluorescent ROS sensors [43]. Moreover,
treatment with bafilomycin A1 (a lysosomal ATPase inhibitor), ammonium chloride (which
neutralizes acidic organelles such as lysosomes), or PepA-Me (a lysosomal aspartyl protease
inhibitor) suppressed ferroptosis induced by erastin and RSL3 and decreased lysosomal ROS
and ferroptotic cell death–associated ROS. These studies suggest the possible involvement of
lysosomal ROS in ferroptosis [43].
However, it was recently found that preventing accumulation of ferrostatins in lysosomes
by reducing the extent of molecular trapping via the lysosomotropic effect improved the
potency of ferroptosis inhibitors, which indicates that lysosomes are not critical for ferroptotic
suppression [35]. The discovery of the iron-dependent lethal compound ironomycin that
localizes to lysosomes [44] suggests that additional studies concerning the role of lysosomes in
ferroptosis may be needed to evaluate the relationships between lysosomal lipid ROS and cell
death.
How does lipid peroxidation lead to ferroptotic cell death?
Another important open issue is what specifically during the course of lipid peroxidation leads
to ferroptotic cell death. In other words, is the execution mechanism of ferroptosis through
damage to specific membranes or through downstream reactive products? Membrane lipid
peroxidation substantially alters the physical properties of lipid bilayers in terms of disrupted
ion gradients, decreased membrane fluidity, slower lateral diffusion, and increased membrane
permeability [45–48]. One hypothesis is that peroxidized phospholipids can reorient them-
selves and protrude into the aqueous phase, resulting in decreased membrane thickness and in
macrophage recognition [47,49]. Recent molecular dynamics studies suggest that during fer-
roptosis, membrane thinning drives a vicious cycle of increasing access by oxidants, ultimately
resulting in increasing membrane curvature and membrane damage through micelle forma-
tion [50].
Another hypothesis is that formation of protein-based pores is involved in ferroptosis,
resulting in loss of ionic homeostasis [51]. Oxidized PUFA fragments have been hypothesized
to destroy membranes and release toxic reactive fragments into cells, which might interfere
with other cellular processes [52]. Incorporation of long PUFAs into membranes by ACSL4
sensitizes cells to ferroptosis [21]. Another group found that oxidation of ER-associated com-
partments occurs primarily on phosphatidylethanolamines (PEs) and suppression of acyls-ara-
chidonyl and adrenoyl (AdA) esterification into PEs by inhibition of ACSL4 could prevent
ferroptotic cell death [36].
Lipid peroxidation of PUFAs produces a wide variety of oxidation products. Lipid hydro-
peroxides (LOOHs) are the initial products of peroxidation. Secondary products are aldehydes,
among which malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) are most abundant
and exhaustively studied [19]. MDA is produced from decomposition of AAs and larger
PUFAs via enzymatic and nonenzymatic pathways.
The enzymatic process has been extensively studied, whereas little is known about the non-
enzymatic generation of MDA. MDA is the most mutagenic product of lipid peroxidation
because of its capability to react with primary amines on proteins and DNA to form
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crosslinked adducts [53]. Moreover, excessive MDA generation within cells is associated with
major human diseases such as Alzheimer disease, cancer, cardiovascular disease, diabetes, and
Parkinson disease [54]. Decomposition of AAs and longer PUFAs generates 4-HNE [55]. This
highly reactive product of lipid peroxidation contains 3 functional groups: (i) an electrophilic
C = C double bond that is a Michael acceptor and that forms covalent adducts with nucleo-
philic amino acids, (ii) an aldehyde that can form Schiff base adducts with primary amines,
and (iii) a hydroxyl group that can be oxidized to an electrophilic ketone [56].
The electrophile 4-HNE has been widely studied as a signaling molecule that stimulates the
cell cycle and cell proliferation and as a cytotoxic molecule that inhibits gene expression and
promotes the development of disease [19]. Moreover, it has been proposed that 4-HNE can
induce cell death by modulating several transcription factors, such as Nrf2 and peroxisome
proliferator-activated receptors (PPARs), as well as other signaling pathways, such as cell-cycle
regulators and caspases [57]. It has also been found that whether cells undergo apoptosis or
necrosis depends on the cellular concentration of 4-HNE [58]. Finally, selection of erastin-
resistant clones of DU-145 cells revealed that resistant cells had dramatic upregulation of
AKR1C genes, which are involved in detoxifying aldehydes such as 4-HNE [40][59]. A recent
study profiled the protein carbonylation events induced during ferroptosis, presumably
through such electrophilic products of lipid peroxidation [60]. Further studies need to be car-
ried out to define the significance of 4-HNE during ferroptotic cell death.
It is worth noting that lipid peroxidation has also been associated in the literature with
other modes of cell death, including apoptosis, in some cases. There are two key points to note
about these prior studies. First, apoptosis was, for many years, considered synonomous with
cell death, and many studies before the year 2000 simply termed cell death as apoptosis without
any rigorous evaluation of the mode of cell death. Thus, these early studies that refer to apopto-
sis need to be reevaluated to examine the precise mode of cell death involved and whether
indeed ferroptosis may have been induced. Second, in many cases, multiple cell death modes
can be activated by pleiotropic triggers and stresses. Thus, the detection of markers of ferropto-
sis or apoptosis by themselves don’t illuminate the lethal death mechanism involved. In such
cases, detection of lipid peroxidation during apoptosis may simply reflect a low-level stimula-
tion of ferroptosis during apoptotic cell death. However, the possibility does remain that other
models of cell death might be associated with nonlethal degrees of lipid peroxidation; such
cases need to be carefully examined.
Solving the mysteries
Some clues have emerged, pointing to possible solutions to these three mysteries. Regarding
the mechanism of lipid peroxidation, as noted above, both Fenton chemistry and LOXs may
contribute to ferroptosis. Iron metabolism and availability play key roles in both processes. It
has been observed that decreased cellular iron levels suppress erastin lethality in PHKG2-
silenced cells, indicating that phosphorylase b kinase γ 2 (PHKG2) regulates ferroptosis
through regulation of labile iron [12]. Ferritinophagy, the autophagic degradation of ferritin,
contributes to iron availability for Fenton chemistry and is involved in ferroptosis [61]. Addi-
tional links between iron metabolism and ferroptosis may help in clarifying the role of iron in
ferroptosis. In addition, lipidomic studies may help to identify substrates of LOXs during fer-
roptotic cell death and to define which ferroptosis contexts primarily use LOXs versus Fenton
chemistry.
Where lipid peroxidation occurs during ferroptosis is the second significant mystery. The
plasma membrane, mitochondria, ER, and lysosomes are all candidates. As noted above, mito-
chondria-deficient cells revealed that mitochondria are not required for ferroptotic cell death.
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By reducing the extent of molecular trapping through the lysosomotropic effect, lysosomes
were also shown to be unnecessary for erastin-induced and RSL3-induced cell death, as well as
ferroptosis suppression by ferrostatins. Moreover, when SRS imaging was used to detect the
localization of a diyne ferrostatin, no detectable signal was found in the plasma membrane.
Therefore, we hypothesize that the ER might be a key subcellular location for ferroptosis, at
least in the cancer cell lines studied in these experiments. Lipid peroxidation during ferroptosis
may as well occur in multiple organelles. The vulnerability of each organelle to lipid peroxida-
tion may be different because of differences in lipid compositions, iron storage, GSH level,
LOX expression, and GPX4 localization. For example, mitochondria are rich in iron and
GPX4. Depletion of mitochondria might change the cellular level of iron and GPX4 and regu-
late ferroptosis in other organelles. Defining the lipid composition of different organelles and
how these lipids promote or suppress lipid peroxidation and ferroptosis may aid in solving this
mystery.
Recently, a study reported that cyclic-di-adenosine monophosphate (c-di-AMP) in live
gram-positive bacteria could interact with the innate sensor stimulator of interferon genes
(STING) to mediate ER stress and induce mechanistic target of rapamycin (mTOR) inactiva-
tion, resulting in ER-phagy [62]. This study provides a strategy to induce ER-phagy in cells. To
date, three proteins (family with sequence similarity 134 member B [FAM134B], SEC62, and
reticulon-3 [RTN3]) have been identified as ER-phagy receptors in mammalian cells [63–65];
further elucidation of the components of this process may reveal links to ferroptosis. Since
generation of mitochondria-deficient cells was possible using mitophagy, perhaps it will be
possible to generate ER-deficient cells using ER-phagy. Moreover, as noted, ER stress, UPR,
and subsequent ER-associated protein degradation (ERAD) are other key issues that may be
linked to ferroptosis, and resolving their relationships may be informative. The ER membrane
protein complex (EMC) might also function in both ERAD and ferroptotic cell death [66]. It is
possible that ER stress is simply a consequence of GSH depletion during ferroptosis and does
not contribute to the lethal mechanism, but more studies are needed to address this question.
How lipid peroxidation leads to ferroptosis is the third open question. Computational
approaches such as molecular dynamics simulations may aid the study of membrane proper-
ties during ferroptosis. The secondary products of lipid peroxidation, such as MDA and
4-HNE, may also be good targets to examine for their roles during ferroptosis. Although these
two aldehydes have been extensively studied, and excessive accumulation of 4-HNE has been
shown to promote apoptosis and necrosis, their role in ferroptosis is unclear. By solving these
mysteries of ferroptosis, we may discover new insights and therapeutic strategies for ferropto-
sis-related human diseases, such as numerous cancers and degenerative diseases.
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